Celyad is looking for partners for both its cardiology and immuno-oncology programs
Cardiology assets that are available for out-licensing
Celyad is currently seeking partnerships to accelerate further development and commercialization of C-Cure®
- C-Cure®: first-in-class reparative therapy for heart failure treatment.
- C-Cathez™ : unique intraventricular injection catheter (video)
- Heart Access Technology (video)
Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets. An exclusive mandate was given to Piper Jaffray, a well reputated international investment bank and asset management firm, to support the company in the partnering and/or the externalization of C-Cure®.
Immuno-Oncology assets that are available for licensing agreement
We look forward to continue offering access, through licensing agreement, to our CAR-T Allogeneic patent for your own allogeneic product development.
CAR-T Allogeneic patent: as from November 10th, 2015, our allogeneic T-Cell portfolio includes the US Patent 9,181,527 as well as patent applications relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). The granted product claims of the US Patent 9,181,527 are not limited to specific CARs or specific methods of generating allogeneic CAR T-Cells, such as genome editing or genetic engineering. The patented products are applicable for use in treating various human disease conditions such as cancer, chronic infectious diseases, and autoimmunity.
Celyad announces collaboration with Institut Curie for the development of its immuno-oncology program NKR-T
Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets
Want to see more?